CN101500559B - 用于认知恢复和运动恢复的磷酸二酯酶4抑制剂 - Google Patents

用于认知恢复和运动恢复的磷酸二酯酶4抑制剂 Download PDF

Info

Publication number
CN101500559B
CN101500559B CN200780026381.9A CN200780026381A CN101500559B CN 101500559 B CN101500559 B CN 101500559B CN 200780026381 A CN200780026381 A CN 200780026381A CN 101500559 B CN101500559 B CN 101500559B
Authority
CN
China
Prior art keywords
training
cognitive
creb
animal
recovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780026381.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN101500559A (zh
Inventor
T·M·哈勒姆
R·博尔特舒拉德泽
T·塔利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dart Neuroscience LLC
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of CN101500559A publication Critical patent/CN101500559A/zh
Application granted granted Critical
Publication of CN101500559B publication Critical patent/CN101500559B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
CN200780026381.9A 2006-05-19 2007-05-18 用于认知恢复和运动恢复的磷酸二酯酶4抑制剂 Expired - Fee Related CN101500559B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80194906P 2006-05-19 2006-05-19
US60/801,949 2006-05-19
PCT/US2007/069279 WO2007137181A2 (en) 2006-05-19 2007-05-18 Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation

Publications (2)

Publication Number Publication Date
CN101500559A CN101500559A (zh) 2009-08-05
CN101500559B true CN101500559B (zh) 2014-01-08

Family

ID=38617977

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780026381.9A Expired - Fee Related CN101500559B (zh) 2006-05-19 2007-05-18 用于认知恢复和运动恢复的磷酸二酯酶4抑制剂

Country Status (11)

Country Link
EP (2) EP2021001B1 (https=)
JP (2) JP2009537568A (https=)
CN (1) CN101500559B (https=)
AU (1) AU2007253734B2 (https=)
BR (1) BRPI0711816A2 (https=)
CA (1) CA2653042C (https=)
ES (1) ES2412481T3 (https=)
IL (1) IL195295A (https=)
MX (1) MX2008014713A (https=)
SG (2) SG172602A1 (https=)
WO (1) WO2007137181A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12426785B2 (en) * 2019-12-23 2025-09-30 Peter Anthony HALL Method and system for assessing cognitive function of an individual

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316531A1 (en) * 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Augmented cognitive training
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
KR20110049801A (ko) * 2008-07-18 2011-05-12 다트 뉴로사이언시즈, 엘엘씨 기억 물질의 평가를 위한 방법 및 시스템
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
JP6325254B2 (ja) * 2011-09-30 2018-05-16 公益財団法人東京都医学総合研究所 サイクリックａｍｐ応答配列結合タンパク質遺伝子解析による薬物感受性および疾患脆弱性の評価方法
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091609A2 (en) * 2001-08-10 2004-10-28 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
CN1604776A (zh) * 2001-10-16 2005-04-06 记忆药物公司 作为用于治疗神经病综合症的pde－4抑制剂的4－(4－烷氧基－3－羟基苯基)－2－吡咯烷酮衍生物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2578001B2 (ja) * 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
EP0651824A4 (en) 1992-04-10 1997-02-26 Fox Chase Cancer Center TRANSCRIPTION ELEMENT FOR CONTROLLING THE INCREASED GENE EXPRESSION IN MYOBLASTEN.
JP2001508020A (ja) * 1994-06-02 2001-06-19 シエーリング アクチエンゲゼルシヤフト 多発性硬化症治療用のｐｄｅ ｉｖ阻害剤
US6689557B1 (en) 1994-10-07 2004-02-10 Cold Spring Harbor Laboratory Method of identifying a substance that affects long term memory and CREM/CREB/ATF-1 subfamily members
US5929223A (en) 1994-10-07 1999-07-27 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
DE69919179T2 (de) 1998-09-09 2005-07-28 Inflazyme Pharmaceuticals, Ltd., Richmond Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
IT1303272B1 (it) 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
EP1157007A1 (en) 1999-02-25 2001-11-28 Merck Frosst Canada Inc. Pde iv inhibiting compounds, compositions and methods of treatment
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
CA2402384A1 (en) 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Ltd. Benzylated pde4 inhibitors
EP2316531A1 (en) * 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Augmented cognitive training
EP1343528A2 (en) * 2000-11-02 2003-09-17 Research Foundation of City University of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
EP1482916A4 (en) * 2002-02-07 2007-12-12 Univ Miami SCHWANNZELLEN AND PHOSPHODIESTERASE-HEMMER BASED THERAPY
DK1610796T3 (da) * 2003-03-17 2014-07-21 Neurohealing Pharmaceuticals Inc Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade
US20090298864A1 (en) * 2005-04-11 2009-12-03 The Trustees Of Columbia University In The City Of New York Methods for Treating Mild Cognitive Impairment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091609A2 (en) * 2001-08-10 2004-10-28 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
CN1604776A (zh) * 2001-10-16 2005-04-06 记忆药物公司 作为用于治疗神经病综合症的pde－4抑制剂的4－(4－烷氧基－3－羟基苯基)－2－吡咯烷酮衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gregory M. Rose等.Phosphodiesterase inhibitors for cpgnitive enhancement.《Current Pharmaceutical Design》.2005,第11卷(第26期),3331-3332. *
Rusiko Bourtchouladze等.a mouse model of rubingstein-taybi syndrome :defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4.《PROCEEDINGS of the National Academy of sciences of usa, National Academy of sciences,washingston》.2003,第100卷(第18期),10518-10522. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12426785B2 (en) * 2019-12-23 2025-09-30 Peter Anthony HALL Method and system for assessing cognitive function of an individual

Also Published As

Publication number Publication date
SG10201407258RA (en) 2015-01-29
IL195295A (en) 2015-11-30
WO2007137181A2 (en) 2007-11-29
AU2007253734B2 (en) 2013-07-25
BRPI0711816A2 (pt) 2011-12-13
EP2021001B1 (en) 2012-12-12
HK1130656A1 (en) 2010-01-08
EP2377533A3 (en) 2012-02-22
AU2007253734A1 (en) 2007-11-29
EP2377533A2 (en) 2011-10-19
CN101500559A (zh) 2009-08-05
SG172602A1 (en) 2011-07-28
CA2653042A1 (en) 2007-11-29
JP2009537568A (ja) 2009-10-29
ES2412481T3 (es) 2013-07-11
WO2007137181A3 (en) 2008-08-07
EP2021001A2 (en) 2009-02-11
IL195295A0 (en) 2009-08-03
JP2015042667A (ja) 2015-03-05
CA2653042C (en) 2016-07-05
MX2008014713A (es) 2009-04-17

Similar Documents

Publication Publication Date Title
US8455538B2 (en) Augmented cognitive training
CN101500559B (zh) 用于认知恢复和运动恢复的磷酸二酯酶4抑制剂
US9931318B2 (en) Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
EP2156831B1 (en) HT0712 for treating a cognitive deficit
US7868015B2 (en) Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US9795591B2 (en) Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
HK1130656B (en) Phosphodiesterase 4 inhibitors for motor rehabilitation
HK1157693A (en) Augmented cognitive training
HK1087351B (en) Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
HK1159514B (en) Ht0712 for the treatment of a cognitive deficit

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: DART NEUROSCIENCE (CAYMAN) LTD.

Free format text: FORMER OWNER: HELICON THERAPEUTICS INC.

Effective date: 20140106

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140106

Address after: Grand Cayman, Cayman Islands

Patentee after: Dart Neuroscience LLC

Address before: American California

Patentee before: Helicon Therapeutics Inc.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140108

Termination date: 20180518

CF01 Termination of patent right due to non-payment of annual fee